Cancer Antigens

Tumor vaccine raises antigen-specific response in gastric cancer patients

Published in Gene Therapy Weekly, December 12th, 2002

by Sonia Nichols, senior medical writer - Medical collaborators in Japan and Sweden have completed a phase I trial of peptide-pulsed dendritic cells in gastric cancer patients.

Scientists have identified the tumor-associated antigen HER-2/neu in some gastric cancers. Previous studies have shown dendritic cells made to overexpress the oncogene HER-2/neu act as cancer antigens in tumor vaccines. Medical researchers are currently evaluating whether or not such vaccines would be effective for treating gastric cancer.

Koji Kono and colleagues, Yamanashi Medical University, Japan, collaborated with medical investigators at Karolinska Hospital in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-12-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry